Emily Mandell co-wrote this blog post with Yasasvi Popuri.
What clinical profile should our pipeline drug pursue to compete in a crowded market? For which patients will our drug be preferred and why? How will the adoption of our in-market drug change with upcoming biosimilars, competitive launches and changing guidelines? These multibillion-dollar questions are very familiar to commercial and medical teams of pharmaceutical and biotech companies, but just how do they feel about answering them? Simply put: uncertain.